Avisi technologies is a pre-clinical stage company developing a nanotechnology-enabled defense against blindness from glaucoma.
Avisi is developing VisiPlate, a nanotechnology-enabled ocular implant for treating glaucoma. Glaucoma is the world’s leading cause of irreversible blindness and will affect over 160 million people in 2025. In glaucoma patients, excess aqueous humor builds up inside the eye, putting pressure on and permanently damaging the optic nerve. VisiPlate is a novel drainage implant that creates a new outflow pathway for aqueous humor in the eye. VisiPlate’s small scale, nonfibrotic materials, and unique multi-channel design will translate to greater safety, efficacy, and value for patients and stakeholders.
VisiPlate is 20x thinner than a human hair and aims to safely reduce eye pressure in glaucoma patients, while minimizing the risk of patient discomfort and device failure from scarring.
Avisi was founded in 2017 and is a spinout of the University of Pennsylvania.